Everything tagged "insider buying" across the TickerSpark archives.
Braveheart Bio has a credible bull case as insider-aligned capital backs a lead program with positive Phase 2 data and a late-stage path. The single-asset risk is real, but the size of recent buying makes today’s IPO pullback look more like volatility than a thesis break.
Three insiders bought $9.29 million of BSX shares in roughly two weeks, including a roughly $9 million purchase by CEO Michael Mahoney. That confidence signal lands alongside 19.9% revenue growth, 55.6% EPS growth and a valuation that already reflects a reset.
NMM’s bull case rests on $4.1 billion of contracted revenue, 99.5% fleet utilization and a 6.8x trailing P/E—not a vague shipping-cycle promise. The reported $846.87 million of insider buying adds a powerful signal, though the freshest filings do not fully verify an extraordinary open-market purchase.
Summit Therapeutics is trading like the financing scare already came and went. The rebound says the market cares more about ivonescimab's November 14, 2026 FDA clock and funded Phase III runway than a headline offering that never even closed.
Summit’s financing headline looks ugly, but the insider tape says management is still leaning into ivonescimab rather than backing away from it. When co-CEOs and the CFO buy more than $100 million of stock right into a raise, dilution stops looking like the whole story.
Generate AI research on any ticker — grades, price targets, and full analysis in minutes.
Open the GeneratorCancel anytime